Willkie Farr & Gallagher LLP
03/30/2026 | News release | Distributed by Public on 03/30/2026 10:11
Willkie Advises CVC on Sale of Minority Stake in Syntegon to Apollo
Willkie Advises CVC on Sale of Minority Stake in Syntegon to Apollo
News
share
March 30, 2026
Willkie is representing CVC Capital Partners in the sale of 37% of its stake in Syntegon, a leading technology company and strategic partner to the pharmaceutical, biotechnology and food industries, to an investor group led by Apollo-managed funds.
CVC recently announced that an Apollo-led investor group is acquiring a 37% minority stake in Syntegon, with CVC retaining its majority stake with the remaining 63% of shares. The partnership is expected to accelerate Syntegon's next growth phase including its expansion in the North American market.
Willkie previously advised CVC on its acquisition of Syntegon in 2020.
Syntegon, headquartered in Stuttgart, provides in-depth process expertise and mission-critical technologies to the pharmaceutical and biotechnology sectors for the production of essential medicines, as well as high-speed, high-precision packaging solutions for the food sector.
CVC is a leading global private markets manager with a network of 30 office locations throughout EMEA, the Americas, and Asia, with €205 billion of assets under management.
The Willkie team is led by partners Georg Linde and Dr. Nils Röver and includes partners Jacob Ahme, Dr. Sebastian Häfele, Daniel Gendron, Timothy Sawyer, Dr. Bettina Bokeloh and Dr. Georg Weidenbach, counsel Martin Waśkowski, and associates Nils Bock, Melina Terwesten and Dr. Florian Kalbfleisch.
CVC recently announced that an Apollo-led investor group is acquiring a 37% minority stake in Syntegon, with CVC retaining its majority stake with the remaining 63% of shares. The partnership is expected to accelerate Syntegon's next growth phase including its expansion in the North American market.
Willkie previously advised CVC on its acquisition of Syntegon in 2020.
Syntegon, headquartered in Stuttgart, provides in-depth process expertise and mission-critical technologies to the pharmaceutical and biotechnology sectors for the production of essential medicines, as well as high-speed, high-precision packaging solutions for the food sector.
CVC is a leading global private markets manager with a network of 30 office locations throughout EMEA, the Americas, and Asia, with €205 billion of assets under management.
The Willkie team is led by partners Georg Linde and Dr. Nils Röver and includes partners Jacob Ahme, Dr. Sebastian Häfele, Daniel Gendron, Timothy Sawyer, Dr. Bettina Bokeloh and Dr. Georg Weidenbach, counsel Martin Waśkowski, and associates Nils Bock, Melina Terwesten and Dr. Florian Kalbfleisch.
Related Practice Areas
Related Locations
Frankfurt
An der Welle 4
D-60322 Frankfurt am Main
Hamburg
Poststraße 6
20354 Hamburg
Munich
Brienner Straße 22
D-80333 Munich
Willkie Farr & Gallagher LLP published this content on March 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 30, 2026 at 16:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]